Summary
Gilead Sciences, Inc. (GILD) filed a Form 8-K on April 23, 2003, to report its earnings for the quarter ended March 31, 2003, via an accompanying press release (Exhibit 99.1). The filing primarily serves as a disclosure mechanism for these financial results. Management emphasized the use of non-GAAP financial measures, explaining that these are presented to provide investors with a clearer view of operating trends by excluding an unusual, infrequent in-process research and development charge related to an acquisition. The company highlighted that this non-GAAP presentation is intended to offer crucial insights into the core business's performance, allowing for a better understanding of underlying operational trends independent of the impact of this specific acquisition-related charge. Investors should refer to the press release for detailed financial figures and the specific nature of the non-GAAP adjustments.
Key Highlights
- 1Gilead Sciences, Inc. announced its first-quarter 2003 earnings on April 23, 2003.
- 2The earnings announcement was made via a press release filed as Exhibit 99.1 to the 8-K.
- 3The company utilized non-GAAP financial measures in its earnings release.
- 4Management believes non-GAAP measures provide better insight into core operating results and trends.
- 5An in-process research and development (IPRD) charge related to an acquisition was the primary item excluded from GAAP.
- 6The IPRD charge is described as unusual due to its nature, size, and infrequency.
- 7The CFO, John F. Milligan, signed the report.